Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.57 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27450496 | 1.00 | CTSK (0.57) | CTSKCTSSCTSBCTSLSLC1A3 | |
| SCHEMBL8408312 | 0.89 | CTSK (0.61) | CTSKCTSSCTSBCTSLSLC1A3 | |
| SCHEMBL7166483 | 0.86 | AAK1 (0.52) | CTSKCTSSCTSBCTSLLARS1 | |
| SCHEMBL6984362 | 0.86 | CTSK (0.52) | CTSKCTSSCTSBCTSLSLC1A3 | |
| SCHEMBL7328656 | 0.85 | LTA4H (0.55) | CTSKCTSSCTSBCTSL | |
| SCHEMBL7328660 | 0.85 | LTA4H (0.55) | CTSKCTSSCTSBCTSL | |
| SCHEMBL11072087 | 0.85 | CTSK (0.60) | CTSKCTSSCTSBCTSLSLC1A3 | |
| SCHEMBL5906852 | 0.84 | CTRB1 (0.54) | CTSKCTSSCTSBCTSLSLC1A3 | |
| SCHEMBL5906855 | 0.84 | CTRB1 (0.54) | CTSKCTSSCTSBCTSLSLC1A3 | |
| SCHEMBL6703437 | 0.83 | CTSK (0.54) | CTSKCTSSCTSBCTSLSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1019046-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
| US-20020049316-A1 | Protease inhibitors | HALBERT STACIE MARIE (US) | 2002-04-25 | — | — | US | disclosed |
| CN-1341590-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1341592-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998046582-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
| US-5414013-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5414017-A | Cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0449523-B1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | SQUIBB & SONS INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5223516-A | Endopeptidase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0449523-A1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | E.R. SQUIBB & SONS, INC. (US) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049316-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885CTSS 8/4885CTSB 4/4885 |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | CTSK 64/4885CTSS 4/4885CTSB 35/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885CTSS 8/4885CTSB 4/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885CTSS 8/4885CTSB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.